GE rolls out 'factory-in-a-box' service for virus-based therapies: 4 things to know

General Electric will launch prefabricated manufacturing units for virus-based gene and cell therapies, vaccines and cancer treatments, the company announced April 17.

Here are four things to know.

1. Demand for these types of therapies, which use engineered viruses to introduce healthy genetic material into sick patients' cells, has skyrocketed.

2. GE aims to provide a "factory-in-a-box" service with its Kubio manufacturing units to help drugmakers increase production capacity for the viral-vector-based medicines, according to Reuters.

3. The company already produces off-the-shelf modular factories for other complex biologics like monoclonal antibodies. However, the Kubio factories for viral-vector medicines are much cheaper and faster to build.

4. A GE spokesperson told Reuters the company is already in talks with several potential customers for the new Kubio factories.

More articles on supply chain:

Amazon warehouse workers urinate in bottles to avoid discipline for 'idle time,' undercover author finds
'We can't view ourselves as the box pushers of a hospital': 3 experts discuss the evolving hospital supply chain
CVS Health elevates Kevin Hourican to president of CVS Pharmacy: 4 things to know

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars